Endpoints of clinical trials for muscle-invasive bladder cancer.
Tannock
I F
IF
Dept. of Medicine, Princess Margaret Hospital, University of Toronto, Ontario, Canada.
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000379:methods*; D006801:Humans; D009132:Muscles / Q000473:pathology; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D010865:Pilot Projects; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D015996:Survival Rate; D001749:Urinary Bladder Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*
D000970:Antineoplastic Agents